Abstract
Hematopoietic stem cell transplantation has become an established treatment for some patients with malignant and non-malignant hematologic diseases. More wide-spread use of this treatment modality is limited by its severe side effects. Graft-versus-host disease is a major cause of morbidity and mortality following allogeneic stem transplantation. Recent data from experimental research in murine models of GVHD and early stage clinical studies demonstrate the potential of statins in the prevention and treatment of acute and chronic GVHD. Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, the rate limiting enzyme of the mevalonate pathway. They are an already approved drug class with a well known toxicity profile. Besides lowering of cholesterol levels other pleiotropic effects contribute to the therapeutic activity of statins. Statins have immunomodulatory effects and inhibit a broad range of immune cells that play a role in the pathogenesis of GVHD, including antigen-presenting cells. In addition to preventing GVHD statins possess several other effects that might prove beneficial in the setting of allogeneic transplantation, such as cardiovascular protection and anti-neoplastic activity. Here we review the current knowledge on the use and effects of statins in patients who undergo allogeneic hematopoietic stem cell transplantation with a special focus on prevention and treatment of GVHD.
Current Stem Cell Research & Therapy
Title: The Use of Statins in Hematopoietic Stem Cell Transplantation
Volume: 4 Issue: 4
Author(s): Alexander Shimabukuro-Vornhagen, Jan Glossmann, Tanja Liebig, Christof Scheid and Michael von Bergwelt-Baildon
Affiliation:
Abstract: Hematopoietic stem cell transplantation has become an established treatment for some patients with malignant and non-malignant hematologic diseases. More wide-spread use of this treatment modality is limited by its severe side effects. Graft-versus-host disease is a major cause of morbidity and mortality following allogeneic stem transplantation. Recent data from experimental research in murine models of GVHD and early stage clinical studies demonstrate the potential of statins in the prevention and treatment of acute and chronic GVHD. Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, the rate limiting enzyme of the mevalonate pathway. They are an already approved drug class with a well known toxicity profile. Besides lowering of cholesterol levels other pleiotropic effects contribute to the therapeutic activity of statins. Statins have immunomodulatory effects and inhibit a broad range of immune cells that play a role in the pathogenesis of GVHD, including antigen-presenting cells. In addition to preventing GVHD statins possess several other effects that might prove beneficial in the setting of allogeneic transplantation, such as cardiovascular protection and anti-neoplastic activity. Here we review the current knowledge on the use and effects of statins in patients who undergo allogeneic hematopoietic stem cell transplantation with a special focus on prevention and treatment of GVHD.
Export Options
About this article
Cite this article as:
Shimabukuro-Vornhagen Alexander, Glossmann Jan, Liebig Tanja, Scheid Christof and Bergwelt-Baildon von Michael, The Use of Statins in Hematopoietic Stem Cell Transplantation, Current Stem Cell Research & Therapy 2009; 4 (4) . https://dx.doi.org/10.2174/157488809789649250
DOI https://dx.doi.org/10.2174/157488809789649250 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Co-Editor
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Novel Inflammatory Biomarkers in Cardiovascular Disease: From Molecular Mechanisms to Therapeutic Targets (Part-II))
Current Medicinal Chemistry NLRP3 Inflammasome in the Pathophysiology of Hemorrhagic Stroke: A Review
Current Neuropharmacology A Review on Corrosion Protection of Iron and Steel
Recent Patents on Corrosion Science (Discontinued) Trends in Nanotechnology Patents Applied to the Health Sector
Recent Patents on Nanotechnology Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design Redefining the Roles of Aspirin across the Spectrum of Cardiovascular Disease Prevention
Current Cardiology Reviews Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Pathogenesis and Subtype of Intracerebral Hemorrhage (ICH) and ICH Score Determines Prognosis
Current Neurovascular Research Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Cystatin C in Cerebrovascular Disorders
Current Neurovascular Research Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design The Appearance of Middle Meningeal Artery Fistulae After Willis Covered Stent for Traumatic Carotid-cavernous Fistulae: Two Case Reports
Current Medical Imaging Endothelin-1 and Human Platelets
Current Vascular Pharmacology Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry Prevention of Immune-mediated Transfusion-related Acute Lung Injury; from Bloodbank to Patient
Current Pharmaceutical Design The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology